Introduction: Bioprospected microalgae collected from water bodies in Northern Ontario, Canada, have been shown to produce bioactive molecules, including carotenoids, polysaccharides, vitamins, and lipids, which exhibit significant pharmacological potential. Several studies have confirmed that extracts from these microalgae possess antioxidant, antimicrobial, and anticancer properties. Cancer, one of the leading causes of global mortality, is responsible for millions of deaths each year. This disease results from genetic and epigenetic alterations that disrupt critical cellular pathways, leading to uncontrolled cell growth, enhanced migratory and invasive capabilities, and resistance to immune system defenses. Conventional treatment strategies, such as surgery, radiotherapy, and chemotherapy, have notable limitations, including systemic toxicity and tumor resistance, which often result in therapeutic failure. Therefore, searching for novel molecules with antitumor potential is essential to provide alternative treatment options for patients unresponsive to current therapies. Objective: This study aims to evaluate the in vitro antitumor potential of various microalgae extracts against tumor cell lines. Materials and Methods: Bioprospected microalgae strains S5, P981 (Coccomyxa sp.), LL1 (Scenedesmus sp.), LL2A, and CC (Chlamydomonas sp.) were cultured for 14 days in Bold's Basal Medium (BBM) at pH 7 under 16-hour light/8-hour dark cycles at 25°C, with continuous agitation at 150 rpm. After harvesting, methanol, ethanol, and aqueous extraction were performed on each strain. The extracts were concentrated under vacuum, and the crude extracts were weighed. DMSO was then added to obtain a stock solution of microalgae extracts (ME) at 10 mg/mL. Tumor cell lines K562, MCF7, HCT-116, SKMEL-19, and AGP-01 were plated in 96-well plates, and microalgae extracts were added in a single dose (100 µg/mL) or in a concentration-response curve (200 µg/mL – 3.125 µg/mL) for 72 hours to evaluate cell viability and the Half-Maximal Inhibitory Concentration (IC50) of the most cytotoxic extracts using the MTT method. Results: Fifteen extracts were produced, with the methanolic extracts from S5 and LL2A showing activity against the MCF7 breast cancer cell line and the SKMEL-19 melanoma cell line, respectively. The ethanolic extracts from CC, LL2A, and P981 exhibited antileukemic activity against the K562 cell line, with IC50 values ranging from 78 to 96 µg/mL. Additionally, the aqueous extract from S5 demonstrated cytotoxic potential against the AGP-01 gastric cancer cell line. Conclusion: Initial results indicate that extracts derived from green microalgae exhibit high antitumoral potential against various tumor types, positioning them as a promising source of new pharmacologically active compounds. Further research is needed to identify the specific compounds responsible for the antitumor activity in each extract, as well as to better understand their mechanisms of action both in vitro and in vivo across different tumor types.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
